OCEAN(a)-DOSE试验中接受安慰剂治疗患者的血清脂蛋白(a)浓度的个体内变异性 - Suppr | 超能文献

相似文献

1

Intraindividual Variability in Serial Lipoprotein(a) Concentrations Among Placebo-Treated Patients in the OCEAN(a)-DOSE Trial.OCEAN(a)-DOSE试验中接受安慰剂治疗患者的血清脂蛋白(a)浓度的个体内变异性

J Am Coll Cardiol. 2025 Feb 11;85(5):550-553. doi: 10.1016/j.jacc.2024.10.081. Epub 2024 Dec 11.

2

Small Interfering RNA to Reduce Lipoprotein(a) in Cardiovascular Disease.小干扰 RNA 降低心血管疾病中的脂蛋白(a)。

N Engl J Med. 2022 Nov 17;387(20):1855-1864. doi: 10.1056/NEJMoa2211023. Epub 2022 Nov 6.

3

The Off-Treatment Effects of Olpasiran on Lipoprotein(a) Lowering: OCEAN(a)-DOSE Extension Period Results.奥帕西朗停药后对脂蛋白(a)降低的影响：OCEAN(a)-DOSE 扩展期结果。

J Am Coll Cardiol. 2024 Aug 27;84(9):790-797. doi: 10.1016/j.jacc.2024.05.058.

4

Study design and rationale for the Olpasiran trials of Cardiovascular Events And lipoproteiN(a) reduction-DOSE finding study (OCEAN(a)-DOSE).奥拉西壬临床试验的设计与原理——心血管事件和脂蛋白(a)降低剂量发现研究（OCEAN(a)-DOSE）。

Am Heart J. 2022 Sep;251:61-69. doi: 10.1016/j.ahj.2022.05.004. Epub 2022 May 16.

5

Single Ascending and Multiple-Dose Trial of Zerlasiran, a Short Interfering RNA Targeting Lipoprotein(a): A Randomized Clinical Trial.单次递增和多次给药试验：靶向脂蛋白(a)的短干扰 RNA 药物 Zerlasiran：一项随机临床试验。

JAMA. 2024 May 14;331(18):1534-1543. doi: 10.1001/jama.2024.4504.

6

Lepodisiran, an Extended-Duration Short Interfering RNA Targeting Lipoprotein(a): A Randomized Dose-Ascending Clinical Trial.雷帕霉素靶向载脂蛋白(a)的长持续时间短干扰 RNA（Lepodisiran）：一项随机剂量递增临床试验。

JAMA. 2023 Dec 5;330(21):2075-2083. doi: 10.1001/jama.2023.21835.

7

Olpasiran, Oxidized Phospholipids, and Systemic Inflammatory Biomarkers: Results From the OCEAN(a)-DOSE Trial.奥帕西然、氧化磷脂与全身炎症生物标志物：OCEAN(a)-DOSE试验结果

JAMA Cardiol. 2025 May 1;10(5):482-486. doi: 10.1001/jamacardio.2024.5433.

8

Lepodisiran - A Long-Duration Small Interfering RNA Targeting Lipoprotein(a).乐泊迪西然——一种靶向脂蛋白(a)的长效小干扰RNA

N Engl J Med. 2025 May 1;392(17):1673-1683. doi: 10.1056/NEJMoa2415818. Epub 2025 Mar 30.

9

Bempedoic acid plus ezetimibe fixed-dose combination in patients with hypercholesterolemia and high CVD risk treated with maximally tolerated statin therapy.贝特帕酸联合依折麦布固定剂量复方制剂在最大耐受他汀治疗的高胆固醇血症和高 CVD 风险患者中的应用。

Eur J Prev Cardiol. 2020 Apr;27(6):593-603. doi: 10.1177/2047487319864671. Epub 2019 Jul 29.

10

Large intraindividual variability of olanzapine serum concentrations in adolescent patients.青少年患者中奥氮平血清浓度存在较大的个体内变异性。

Ther Drug Monit. 2008 Feb;30(1):108-12. doi: 10.1097/FTD.0b013e3181633429.

引用本文的文献

1

Lp(a): Global Public Health Concern: Emerging Knowledge and Therapeutic Approaches.脂蛋白(a)：全球公共卫生关注点——新认知与治疗方法

Curr Cardiol Rep. 2025 Jun 25;27(1):104. doi: 10.1007/s11886-025-02255-2.

2

Lipoprotein (a) levels and clinical decision-making: data from a Mexican cohort at a tertiary medical institution.脂蛋白（a）水平与临床决策：来自一家三级医疗机构的墨西哥队列研究数据。

Lipids Health Dis. 2025 May 26;24(1):192. doi: 10.1186/s12944-025-02610-w.

3

2024: The year in cardiovascular disease - the year of lipoprotein(a). Research advances and new findings.